Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
EyePoint, Inc. - Common Stock
(NQ:
EYPT
)
13.12
+0.53 (+4.21%)
Streaming Delayed Price
Updated: 2:50 PM EDT, Mar 25, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about EyePoint, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
Next >
This Fund Bought $28 Million of a Beaten-Down Immunotherapy Stock Last Quarter. What Should Long-Term Investors Know?
↗
March 16, 2026
This biotech develops Nanobody-based therapies targeting chronic inflammatory diseases in dermatology and rheumatology markets.
Via
The Motley Fool
Topics
Regulatory Compliance
This $64 Million Biotech Exit Seemingly Missed a 77% One-Day Surge on Gilead Takeover Deal
↗
March 16, 2026
Arcellx develops cell-based immunotherapies for cancer, leveraging proprietary platforms to address high unmet needs in oncology.
Via
The Motley Fool
Topics
Regulatory Compliance
Biotech Stock Up Nearly 300% Draws $68.7 Million Bet as Breast Cancer Drug Targets 2027 Launch
↗
March 16, 2026
Olema Pharmaceuticals develops targeted therapies for women's cancers, with a lead candidate in clinical trials for breast cancer treatment.
Via
The Motley Fool
Topics
Regulatory Compliance
EyePoint Inc (NASDAQ:EYPT) Stock Falls on Q4 Earnings and Revenue Miss
↗
March 04, 2026
Via
Chartmill
Earnings Scheduled For November 5, 2025
↗
November 05, 2025
Via
Benzinga
Earnings Scheduled For August 6, 2025
↗
August 06, 2025
Via
Benzinga
Analyst Expectations For EyePoint Pharmaceuticals's Future
↗
May 29, 2025
Via
Benzinga
This Biotech Stock Up 700% Is Still a Top Holding Despite a $9.3 Million Sale Last Quarter
↗
March 16, 2026
Praxis Precision Medicines develops clinical-stage therapies for neurological disorders, targeting major unmet needs in CNS therapeutics.
Via
The Motley Fool
Topics
Regulatory Compliance
This Biotech Stock Up Nearly 100% in a Year Has Drawn a New $20 Million Share Investment
↗
March 15, 2026
EyePoint develops sustained-release treatments for retinal diseases, leveraging proprietary technology and strategic industry partnerships.
Via
The Motley Fool
EyePoint (EYPT) Q4 2025 Earnings Call Transcript
↗
March 04, 2026
EyePoint (EYPT) Q4 2025 Earnings Call Transcript
Via
The Motley Fool
Topics
Earnings
Earnings Scheduled For May 7, 2025
↗
May 07, 2025
Via
Benzinga
A Peek at EyePoint Pharmaceuticals's Future Earnings
↗
May 06, 2025
Via
Benzinga
Demystifying EyePoint Pharmaceuticals: Insights From 4 Analyst Reviews
↗
March 06, 2025
Via
Benzinga
Retina’s ‘Sustained’ Moment: Ocular Therapeutix Braces for Game-Changing Phase 3 AXPAXLI Data
February 16, 2026
The multi-billion dollar wet Age-Related Macular Degeneration (wet AMD) market is standing on the precipice of a transformative shift. Today, February 16, 2026, Ocular Therapeutix (NASDAQ: OCUL) is in...
Via
MarketMinute
The Biotech Renaissance: Scientific Breakthroughs and M&A Frenzy Spark a New Bull Market
January 22, 2026
The U.S. biotech sector has officially entered a new golden age. As of January 22, 2026, the industry is witnessing a "renaissance" that has effectively erased the memories of the grueling three-year...
Via
MarketMinute
Topics
Artificial Intelligence
ETFs
Initial Public Offering
Small-Cap Renaissance: Russell 2000 Scales New Heights While Big Tech Stumbles
January 08, 2026
In a dramatic shift that has recalibrated the pulse of Wall Street, the Russell 2000 index (RUT) surged to a new record high on January 8, 2026, signaling a definitive breakout for small-cap stocks. As...
Via
MarketMinute
Topics
Artificial Intelligence
Economy
Intellectual Property
The Great Rotation: Small Caps Lead the Charge as 2026 Trading Opens
January 02, 2026
As the opening bells of 2026 ring across Wall Street, a definitive shift in market leadership is unfolding. In the first trading sessions of the new year, the Russell 2000 index, a benchmark for...
Via
MarketMinute
Topics
Artificial Intelligence
ETFs
Economy
The Small-Cap Renaissance: Why 2026 is the Year of the Russell 2000 and XSU
January 01, 2026
As the sun rises on January 1, 2026, the financial landscape is witnessing a profound shift that many analysts have anticipated for years: the definitive return of the U.S. small-cap sector. After a...
Via
MarketMinute
Topics
Artificial Intelligence
ETFs
Economy
The 2026 Horizon: Technical Breakouts Signal a Sustained Bull Run in AI and Energy
December 31, 2025
As the final trading bell of 2025 rings, the financial markets are closing the year on a high note, characterized by a series of powerful technical breakouts across several high-growth sectors. The S&P...
Via
MarketMinute
Topics
Artificial Intelligence
Economy
Intellectual Property
Is Rapport Therapeutics Stock a Buy After Investment Firm Cormorant Raised Its Stake Over $60 Million?
↗
December 22, 2025
Is Rapport Therapeutics Stock a Buy After Investment Firm Cormorant Raised Its Stake Over $60 Million?
Via
The Motley Fool
Topics
Regulatory Compliance
EyePoint (EYPT) Q3 2025 Earnings Call Transcript
↗
November 05, 2025
EyePoint (EYPT) Q3 2025 Earnings Call Transcript
Via
The Motley Fool
Topics
Earnings
EyePoint Pharmaceuticals Inc (NASDAQ:EYPT) Shares Drop on Q3 Earnings and Revenue Miss
↗
November 05, 2025
EyePoint Pharmaceuticals stock falls after Q3 2025 earnings miss estimates. Despite the financial setback, its key DURAVYU trials for wet AMD are fully enrolled and on track for 2026 data.
Via
Chartmill
Topics
Earnings
12 Health Care Stocks Moving In Wednesday's Intraday Session
↗
October 15, 2025
Via
Benzinga
EyePoint Pharmaceuticals Raises Capital As It Advances Lead Product To Pivotal Study
↗
October 15, 2025
EyePoint Pharmaceuticals outlines Phase 3 trials for Duravyu in diabetic macular edema, backed by $150 million in new funding.
Via
Benzinga
EyePoint (EYPT) Q2 Revenue Drops 44%
↗
August 06, 2025
Via
The Motley Fool
EyePoint Pharmaceuticals Inc (NASDAQ:EYPT) Q2 2025 Earnings Miss Estimates as Shares Drop 4.5% Pre-Market
↗
August 06, 2025
EyePoint Pharmaceuticals (EYPT) Q2 2025 earnings miss estimates with $5.33M revenue and -$0.85 EPS, sparking a 4.5% pre-market drop. Clinical progress in DURAVYU Phase 3 trial offers hope amid...
Via
Chartmill
Topics
Earnings
Forecasting The Future: 4 Analyst Projections For EyePoint Pharmaceuticals
↗
June 17, 2025
Via
Benzinga
Breakout Momentum Plays You May Not Know About
June 06, 2025
Momentum investing is all about timing—these three under-the-radar stocks have begun to rise by still seem to have room for further growth.
Via
MarketBeat
Heico, Monro, Abercrombie & Fitch, Joby Aviation And Other Big Stocks Moving Higher On Wednesday
↗
May 28, 2025
Via
Benzinga
Li Auto, Xponential Fitness And Other Big Stocks Moving Lower In Friday's Pre-Market Session
↗
March 14, 2025
Via
Benzinga
< Previous
1
2
3
4
5
6
7
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
